THE BUSINESS BEHIND THE TEST REPORT

 

BIZ MASALA  |  BUSINESS • ECONOMICS • MARKETS

Inside India’s pharmaceutical testing industry: who competes, who profits, and where the next wave of growth may come from

By Murthy ASR  |  18 October 2026

Hero artwork: editorial illustration created for this story; it is not a photograph of a named laboratory or a depiction of a verified company facility.

The science behind a business

The laboratory is not the last stop in the drug business. It is one of the gates through which a medicine must pass. Behind each stability study, impurity profile or batch-release test sits a business built around scientific capability, regulatory confidence, expensive equipment and repeat customer relationships. As drug products become more complex—and manufacturers serve more regulated markets—the question for investors is not simply whether testing demand will rise. It is which laboratories can convert that demand into sustainable margins.

A market with more than one definition

“Pharmaceutical testing” is not one neatly measured market. It can include analytical testing outsourced by drug makers, bioanalytical work supporting clinical studies, microbiology, stability testing, packaging compatibility and other services. Broader testing, inspection and certification (TIC) estimates include many sectors beyond medicines. Those numbers should not be added together or treated as interchangeable.

Grand View Research estimates the global pharmaceutical analytical testing outsourcing market at US$9.7 billion in 2025, US$10.6 billion in 2026 and US$18.6 billion by 2033. These are market-research estimates and forecasts, not audited totals.

Global market estimates and forecast; the series is a third-party market-research view, not company revenue.

Vimta Labs’ FY2024–25 annual report, citing market research, separately describes India’s pharmaceutical analytical testing outsourcing market as projected to reach US$308.7 million by 2030, with a forecast CAGR of 10.7%. The India and global estimates have different geographies and forecast windows; neither should be mistaken for the revenue of any single company.

India market forecast as cited by Vimta Labs; forecast, not realised sales.

Why manufacturers outsource

Illustrative image: laboratory scientist at work. It is not identified as an employee or facility of a named company.

A drug maker can build and run its own testing facilities, outsource some work, or use a hybrid model. Outsourcing can provide access to specialist instruments and trained scientists without requiring the customer to fund every capability internally. It can also help companies manage variable workloads, meet documentation requirements and obtain expertise for unfamiliar molecules or markets. The trade-off is dependence on external capacity, scheduling and data quality.

·       Routine and repeat testing can support recurring customer relationships, although pricing and utilisation matter.

·       Specialist work—such as impurity profiling, extractables and leachables, peptide characterisation or advanced bioanalysis—can require higher-end equipment and deeper expertise.

·       Regulatory compliance is not just a sales pitch: validated methods, traceable records, controlled processes and reliable data are essential to credibility.

The listed-company signal: Vimta Labs

Vimta is a useful Indian listed-company reference point, but its reported figures should not be presented as revenue from pharmaceutical testing alone. Its services span several testing and research areas. The company’s FY2024–25 annual report reported total income of ₹348.22 crore. Its FY2025–26 financial summary gives total income of ₹416.28 crore, implying growth of approximately 19.5% year on year. Reported EBITDA margin was 35.8% in FY2025–26 against 36.2% in the previous year. These are company-level figures, not a market-wide margin benchmark; readers should verify them against the latest official filing before subsequent updates.

Metric	FY2024–25	FY2025–26	How to read it
Total income	₹348.22 crore	₹416.28 crore	Company-level measure; not pharma-testing-only revenue
Year-on-year growth	—	About 19.5%	Calculated from stated annual totals
EBITDA margin	36.2%	35.8%	Not the same as net profit or free cash flow

 

The commercial lesson is that growth and margins can coexist in a specialised testing business—but they do not eliminate capital intensity. Laboratories need equipment, maintenance, calibration, qualified personnel, quality systems and continuous investment. A high EBITDA margin also does not equal net profit or free cash flow: depreciation, interest, taxes and capital expenditure still matter.

Who is competing—and on what basis?

This is a selected landscape, not a definitive ranking. The companies do not all disclose comparable pharmaceutical-testing revenue, and their service mixes differ. A rigorous market-share table would require consistent definitions and reliable segment-level data that may not be publicly available.

Company / group	Position in the landscape	What readers should compare
Vimta Labs	Indian listed testing and research services company headquartered in Hyderabad	Reported growth, margins, service mix, capacity expansion and customer concentration
SGS	Global testing, inspection and certification group with Indian operations	Life-sciences capabilities and Indian footprint—not total global group revenue
Eurofins	Global laboratory network active in life sciences and analytical testing	Indian services, accreditation, capabilities and segment disclosures
Cotecna / Energon Labs	Cotecna announced acquisition of Hyderabad-based Energon Labs in October 2026	Acquired capabilities, geographic reach and integration; purchase price not stated
Other specialist laboratories	Independent and specialised labs serving pharma, biotech and adjacent sectors	Specialisation, accreditation, turnaround time, customer relationships and scale

 

Cotecna’s Energon acquisition: why it matters

On 16 October 2026, Cotecna announced that it had acquired Energon Labs, a Hyderabad-based analytical testing laboratory. Cotecna said the move strengthens its life-sciences platform and adds capabilities across pharmaceuticals, biopharmaceuticals, medical devices and packaging. The announcement described Energon as cGMP-compliant, USFDA-inspected and certified to ISO 9001:2015 and ISO 17025:2017. It listed services including method development and validation, stability studies, impurity profiling, extractables and leachables, peptide and oligonucleotide characterisation, and packaging compatibility studies.

Illustrative analytical testing equipment; not identified as Energon’s facility.

The strategic logic is straightforward: acquiring an operating laboratory can provide a buyer with local scientific staff, established customer relationships, equipment and specialised methods faster than building everything from scratch. But the announcement did not disclose a purchase price or detailed financials for Energon. We therefore cannot quantify the acquisition’s valuation, its impact on Cotecna’s earnings or its share of the Indian market.

Where growth may come from

Potential growth driver	Commercial opportunity	What could limit it
More complex medicines	Greater need for specialised analytical methods and characterisation	High equipment costs; scarce technical expertise
Biologics, peptides and oligonucleotides	Testing services tailored to complex molecules and product development	Long method-development cycles and demanding validation
Exports and regulated markets	Manufacturers need credible data and compliant testing for target markets	Compliance failures can damage reputation and client relationships
Outsourcing by manufacturers	External labs can provide flexible capacity and specialist capabilities	Customers may bring routine work in-house or negotiate lower prices
Acquisitions and partnerships	Global groups can combine local know-how with international customer access	Integration, scientist retention and harmonising quality systems

 

The laboratory economics: where profit is won or lost

A testing laboratory’s economics depend on more than the price charged for a test. Expensive instruments must be used enough to absorb depreciation and maintenance. Skilled staff and quality systems create a largely fixed cost base. Revenue can fluctuate with customers’ development cycles, regulatory submissions, production schedules and project timing. Long-term contracts may improve visibility, but do not guarantee high margins.

·       Utilisation: idle equipment still costs money; overloaded equipment can delay reports and weaken service quality.

·       Service mix: routine tests and complex analytical work have different price points, labour demands and competitive pressures.

·       Customer concentration: losing a major client can leave capacity underused.

·       Trust and turnaround: accuracy, defensible records and dependable delivery are central to repeat business.

·       Capital discipline: new instruments and facilities need a credible path to demand, not just an optimistic market forecast.

Why Hyderabad matters—but is not guaranteed to win

Hyderabad’s pharmaceutical and biotechnology ecosystem provides a plausible advantage: proximity to manufacturers, research organisations and technical talent can make collaboration easier. The Energon transaction is one concrete example of an international testing group adding a Hyderabad-based laboratory to its network. Still, a city’s manufacturing prominence does not automatically translate into leadership in outsourced testing. That depends on laboratory capability, accreditation, workforce, client trust, infrastructure and the ability to compete on both quality and cost.

The risks behind the growth narrative

·       Market estimates may use different definitions, creating the illusion of a larger addressable market when figures are combined.

·       Forecast growth is not guaranteed revenue. Laboratories must win contracts and maintain utilisation.

·       A regulatory inspection or data-integrity failure can have consequences far beyond one customer or test.

·       New technologies may raise demand, but also require fresh capital spending and retraining.

·       Acquisitions can add capabilities, but value depends on integration, scientist retention and client continuity.

Biz Masala’s takeaway

India’s pharmaceutical testing business sits at the intersection of drug quality, export ambitions, regulation and specialised scientific services. The strongest companies will not necessarily be those with the most instruments or the biggest global parent. They will be the laboratories that can produce reliable, regulator-ready data, retain skilled scientists, keep equipment productively utilised and build durable customer relationships.

For investors, the key questions are practical: how much of a company’s revenue genuinely comes from pharmaceutical testing; what is its service mix; how quickly is it growing; what does it spend on capacity; how concentrated are its customers; and can it preserve margins while investing for more complex work? The industry’s promise is real—but the financial evidence must be examined company by company.

Sources and editorial notes

·       Cotecna, “Cotecna Group Acquires Energon Labs”, 16 October 2026: https://media.cotecna.com/en/media/news/cotecna-group-acquires-energon-labs

·       Grand View Research, Pharmaceutical Analytical Testing Outsourcing Market: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-analytical-testing-outsourcing-market

·       Vimta Labs, investor and financial disclosures: https://vimta.com/investors/

·       Vimta Labs, Annual Report 2024–25: https://vimta.com/wp-content/uploads/Annual-Report-2024-25.pdf

Editorial discipline: Market sizes are third-party estimates or forecasts. Company financials are not directly comparable unless definitions and reporting periods match. The article does not infer acquisition value, market share or company-specific pharmaceutical-testing revenue where it has not been disclosed. Images are illustrative editorial artwork, not verified photographs of the named companies’ premises or staff.

 

BIZ MASALA

Business. Economics. Markets.